{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:24:00Z","timestamp":1789154640461,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Phospholamban (PLN) plays a role in cardiomyocyte calcium handling as primary inhibitor of sarco\/endoplasmic reticulum Ca\n                    <jats:sup>2+<\/jats:sup>\n                    -ATPase (SERCA). The p.(Arg14del) pathogenic variant in the\n                    <jats:italic>PLN<\/jats:italic>\n                    gene results in a high risk of developing dilated or arrhythmogenic cardiomyopathy with heart failure. There is no established treatment other than standard heart failure therapy or heart transplantation. In this study, we generated a novel mouse model with the PLN-R14del pathogenic variant, performed detailed phenotyping, and tested the efficacy of established heart failure therapies eplerenone or metoprolol. Heterozygous PLN-R14del mice demonstrated increased susceptibility to\n                    <jats:italic>ex vivo<\/jats:italic>\n                    induced arrhythmias, and cardiomyopathy at 18 months of age, which was not accelerated by isoproterenol infusion. Homozygous PLN-R14del mice exhibited an accelerated phenotype including cardiac dilatation, contractile dysfunction, decreased ECG potentials, high susceptibility to\n                    <jats:italic>ex vivo<\/jats:italic>\n                    induced arrhythmias, myocardial fibrosis, PLN protein aggregation, and early mortality. Neither eplerenone nor metoprolol administration improved cardiac function or survival. In conclusion, our novel PLN-R14del mouse model exhibits most features of human disease. Administration of standard heart failure therapy did not rescue the phenotype, underscoring the need for better understanding of the pathophysiology of PLN-R14del-associated cardiomyopathy. This model provides a great opportunity to study the pathophysiology, and to screen for potential therapeutic treatments.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-66656-9","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T06:05:07Z","timestamp":1592373907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Tim R.","family":"Eijgenraam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan J.","family":"Boukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.","family":"Boogerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Marloes","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees W. A.","family":"van de Kolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke M.","family":"Stege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter P.","family":"te Rijdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar T.","family":"Hoorntje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"van der Zwaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Peter","family":"van Tintelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman H. W.","family":"Sillj\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"66656_CR1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrm1151","volume":"4","author":"DH MacLennan","year":"2003","unstructured":"MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566\u2013577 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"66656_CR2","volume":"6","author":"M Fish","year":"2016","unstructured":"Fish, M. et al. Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Sci. Rep. 6, 22235 (2016).","journal-title":"Sci. Rep."},{"key":"66656_CR3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1073\/pnas.0510519103","volume":"103","author":"K Haghighi","year":"2006","unstructured":"Haghighi, K. et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. 103, 1388\u20131393 (2006).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"66656_CR4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jacc.2006.07.016","volume":"48","author":"MM DeWitt","year":"2006","unstructured":"DeWitt, M. M., MacLeod, H. M., Soliven, B. & McNally, E. M. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1396\u20131398 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"66656_CR5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12471-019-1247-0","volume":"27","author":"CC Cheung","year":"2019","unstructured":"Cheung, C. C. et al. Phospholamban cardiomyopathy: a Canadian perspective on a unique population. Netherlands Hear. J. 27, 208\u2013213 (2019).","journal-title":"Netherlands Hear. J."},{"key":"66656_CR6","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/eurheartj\/ehz172","volume":"40","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy provides novel insights into disease progression. Eur. Heart J. 40, 1690\u20131703 (2019).","journal-title":"Eur. Heart J."},{"key":"66656_CR7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.hrthm.2009.01.016","volume":"6","author":"MG Posch","year":"2009","unstructured":"Posch, M. G. et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Hear. Rhythm 6, 480\u2013486 (2009).","journal-title":"Hear. Rhythm"},{"key":"66656_CR8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.recesp.2014.11.017","volume":"68","author":"JM L\u00f3pez-Ayala","year":"2015","unstructured":"L\u00f3pez-Ayala, J. M. et al. Phospholamban p.Arg14del mutation in a Spanish family with arrhythmogenic cardiomyopathy: evidence for a European founder mutation. Rev. Espa\u00f1ola Cardiol. (English Ed. 68, 346\u2013349 (2015).","journal-title":"Rev. Espa\u00f1ola Cardiol. (English Ed."},{"key":"66656_CR9","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","volume":"14","author":"PA Van der Zwaag","year":"2012","unstructured":"Van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199\u20131207 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/his.12963","volume":"69","author":"WP Te Rijdt","year":"2016","unstructured":"Te Rijdt, W. P. et al. Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. Histopathology 69, 542\u2013550 (2016).","journal-title":"Histopathology"},{"key":"66656_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ehjci\/jey047","volume":"20","author":"WP Te Rijdt","year":"2019","unstructured":"Te Rijdt, W. P. et al. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur. Heart J. Cardiovasc. Imaging 20, 92\u2013100 (2019).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"66656_CR12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 37, 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"key":"66656_CR13","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori, S. G. et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 36, 2793\u20132867 (2015).","journal-title":"Eur. Heart J."},{"key":"66656_CR14","doi-asserted-by":"publisher","unstructured":"Eijgenraam, T. R., Sillj\u00e9, H. H. W. & de Boer, R. A. Current understanding of fibrosis in genetic cardiomyopathies. Trends Cardiovasc. Med. https:\/\/doi.org\/10.1016\/j.tcm.2019.09.003 (2019).","DOI":"10.1016\/j.tcm.2019.09.003"},{"key":"66656_CR15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1440-1681.2006.04434.x","volume":"33","author":"V Franco","year":"2006","unstructured":"Franco, V. et al. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice. Clin. Exp. Pharmacol. Physiol. 33, 773\u2013779 (2006).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"66656_CR16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ejhf.1406","volume":"21","author":"RA de Boer","year":"2019","unstructured":"de Boer, R. A. et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur. J. Heart Fail. 21, 272\u2013285 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR17","doi-asserted-by":"crossref","first-page":"68E","DOI":"10.1016\/S0002-9149(88)80015-8","volume":"62","author":"H Kirchheim","year":"1988","unstructured":"Kirchheim, H., Ehmke, H. & Persson, P. Physiology of the renal baroreceptor mechanism of renin release and its role in congestive heart failure. Am. J. Cardiol. 62, 68E\u201371E (1988).","journal-title":"Am. J. Cardiol."},{"key":"66656_CR18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/CIRCGENETICS.115.001263","volume":"9","author":"A Milano","year":"2016","unstructured":"Milano, A. et al. Sudden cardiac arrest and rare genetic variants in the community. Circ. Cardiovasc. Genet. 9, 147\u2013153 (2016).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"66656_CR19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12471-013-0401-3","volume":"21","author":"PA Van Der Zwaag","year":"2013","unstructured":"Van Der Zwaag, P. A. et al. Recurrent and founder mutations in the Netherlands - Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Netherlands Hear. J. 21, 286\u2013293 (2013).","journal-title":"Netherlands Hear. J."},{"key":"66656_CR20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yjmcc.2018.08.023","volume":"123","author":"RY Parbhudayal","year":"2018","unstructured":"Parbhudayal, R. Y. et al. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 123, 59\u201363 (2018).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"66656_CR21","first-page":"e003840","volume":"10","author":"M Dewenter","year":"2017","unstructured":"Dewenter, M. et al. Calcium\/calmodulin-dependent protein kinase II activity persists during chronic \u03b2-adrenoceptor blockade in experimental and human heart failure. Circ. Hear. Fail. 10, e003840 (2017).","journal-title":"Circ. Hear. Fail."},{"key":"66656_CR22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.yjmcc.2011.11.012","volume":"52","author":"K Haghighi","year":"2012","unstructured":"Haghighi, K. et al. The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na\/K-ATPase. J. Mol. Cell. Cardiol. 52, 773\u2013782 (2012).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"66656_CR23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/FJC.0b013e318207a35f","volume":"57","author":"S De Jong","year":"2011","unstructured":"De Jong, S., Van Veen, T. A. B., Van Rijen, H. V. M. & De Bakker, J. M. T. Fibrosis and cardiac arrhythmias. J. Cardiovasc. Pharmacol. 57, 630\u2013638 (2011).","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"Suppl","key":"66656_CR24","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/nm1066","volume":"10","author":"CA Ross","year":"2004","unstructured":"Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10(Suppl), S10\u2013S17 (2004).","journal-title":"Nat. Med."},{"key":"66656_CR25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.109.904557","volume":"121","author":"JM Predmore","year":"2010","unstructured":"Predmore, J. M. et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 121, 997\u20131004 (2010).","journal-title":"Circulation"},{"key":"66656_CR26","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI94310","volume":"127","author":"X Fang","year":"2017","unstructured":"Fang, X. et al. Loss-of-function mutations in co-chaperone BAG3 destabilize small HSPs and cause cardiomyopathy. J. Clin. Invest. 127, 3189\u2013200 (2017).","journal-title":"J. Clin. Invest."},{"key":"66656_CR27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1161\/01.RES.0000189262.92896.0b","volume":"97","author":"Q Chen","year":"2005","unstructured":"Chen, Q. et al. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ. Res. 97, 1018\u20131026 (2005).","journal-title":"Circ. Res."},{"key":"66656_CR28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCRESAHA.112.270983","volume":"111","author":"Z Tian","year":"2012","unstructured":"Tian, Z. et al. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. Circ. Res. 111, 532\u2013542 (2012).","journal-title":"Circ. Res."},{"key":"66656_CR29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.yjmcc.2016.11.013","volume":"102","author":"J Li","year":"2017","unstructured":"Li, J. et al. Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 102, 53\u201360 (2017).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"66656_CR30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella, G. G. et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568, 351\u2013356 (2019).","journal-title":"Nature"},{"key":"66656_CR31","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1172\/JCI45709","volume":"121","author":"J Li","year":"2011","unstructured":"Li, J. et al. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia\/reperfusion injury in mice. J. Clin. Invest. 121, 3689\u20133700 (2011).","journal-title":"J. Clin. Invest."},{"key":"66656_CR32","doi-asserted-by":"crossref","first-page":"e5351","DOI":"10.1371\/journal.pone.0005351","volume":"4","author":"A Sanbe","year":"2009","unstructured":"Sanbe, A. et al. Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy. PLoS One 4, e5351 (2009).","journal-title":"PLoS One"},{"key":"66656_CR33","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1172\/JCI70877","volume":"123","author":"MS Bhuiyan","year":"2013","unstructured":"Bhuiyan, M. S. et al. Voluntary exercise and Atg7 overexpression induced autophagy ameliorates cardiac proteinopathy. J. Clin. Invest. 123, 5284\u20135297 (2013).","journal-title":"J. Clin. Invest."},{"key":"66656_CR34","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","volume":"20","author":"MF Hoes","year":"2018","unstructured":"Hoes, M. F. et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur. J. Heart Fail. 20, 910\u2013919 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"66656_CR36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq - A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"66656_CR37","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. 2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"66656_CR38","doi-asserted-by":"publisher","unstructured":"Sergushichev, A. A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv https:\/\/doi.org\/10.1101\/060012 (2016).","DOI":"10.1101\/060012"},{"key":"66656_CR39","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66656_CR40","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/eurjhf\/hfr134","volume":"13","author":"B Bartelds","year":"2011","unstructured":"Bartelds, B. et al. Differential responses of the right ventricle to abnormal loading conditions in mice: Pressure vs. volume load. Eur. J. Heart Fail. 13, 1275\u20131282 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR41","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista, S. R. et al. Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail. 21, 862\u2013873 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR42","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cvr\/cvy187","volume":"114","author":"A Van der Pol","year":"2018","unstructured":"Van der Pol, A. et al. OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovasc. Res. 114, 1871\u20131882 (2018).","journal-title":"Cardiovasc. Res."},{"key":"66656_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15632-x","volume":"7","author":"RK Perera","year":"2017","unstructured":"Perera, R. K. et al. Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4. Sci. Rep. 7, 15222 (2017).","journal-title":"Sci. Rep."},{"key":"66656_CR44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjhf\/hfr152","volume":"14","author":"B Lu","year":"2012","unstructured":"Lu, B. et al. DHRS7c, a novel cardiomyocyte-expressed gene that is down-regulated by adrenergic stimulation and in heart failure. Eur. J. Heart Fail. 14, 5\u201313 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR45","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1073\/pnas.091102398","volume":"98","author":"VB Harding","year":"2001","unstructured":"Harding, V. B., Jones, L. R., Lefkowitz, R. J., Koch, W. J. & Rockman, H. A. Cardiac \u03b2ARK1 inhibition prolongs survival and augments \u03b2 blocker therapy in a mouse model of severe heart failure. Proc. Natl. Acad. Sci. USA 98, 5809\u20135814 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66656_CR46","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/eurjhf\/hfq109","volume":"12","author":"I Kuipers","year":"2010","unstructured":"Kuipers, I. et al. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur. J. Heart Fail. 12, 1042\u20131050 (2010).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cvr\/cvs299","volume":"97","author":"BJ Boukens","year":"2013","unstructured":"Boukens, B. J. et al. Early repolarization in mice causes overestimation of ventricular activation time by the QRS duration. Cardiovasc. Res. 97, 182\u2013191 (2013).","journal-title":"Cardiovasc. Res."},{"key":"66656_CR48","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/eurjhf\/hfs094","volume":"14","author":"MAJ Borgdorff","year":"2012","unstructured":"Borgdorff, M. A. J. et al. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur. J. Heart Fail. 14, 1067\u20131074 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ejhf.243","volume":"17","author":"MV Cannon","year":"2015","unstructured":"Cannon, M. V. et al. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. Eur. J. Heart Fail. 17, 273\u2013282 (2015).","journal-title":"Eur. J. Heart Fail."},{"key":"66656_CR50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55263-y","volume":"9","author":"A Piek","year":"2019","unstructured":"Piek, A. et al. pharmacological myeloperoxidase (MPO) inhibition in an obese\/ hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling. Sci. Rep. 9, 18765 (2019).","journal-title":"Sci. Rep."}],"updated-by":[{"DOI":"10.1038\/s41598-020-70780-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66656-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66656-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66656-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:36:37Z","timestamp":1670312197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66656-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["66656"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-66656-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University Medical Center Groningen, which employs the majority of the authors, has received research grants and\/or fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Novartis, Novo Nordisk, and Roche. R.A.d.B. is a minority shareholder of scPharmaceuticals, and received personal fees from Abbott, AstraZeneca, MandalMed. and Novartis. The other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9819"}}